Issue of Equity, Total Voting Rights and PDMR Dealing

17 July 2017

Instem plc
("Instem" or the "Company")

Issue of Equity, Total Voting Rights and PDMR Dealing

Instem plc (AIM: INS), a leading provider of IT solutions to the global early development healthcare market, announces that, following the exercise of vested EMI share options by an employee, 1,500 ordinary shares of 10p each in the Company (“Ordinary Shares”) have been issued.

Application will be made to the London Stock Exchange for the admission of the 1,500 new Ordinary Shares to trading on AIM. Admission is expected to take place at 8.00am on 19 July 2017.

Total Voting Rights

Following the issue and allotment of the above New Ordinary Shares, the Company's issued share capital comprises 15,866,660 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Therefore the total number of voting rights in the Company is 15,866,660.

The figure of 15,866,660 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

PDMR Dealing

The Company was notified yesterday that on 12 July 2017, the DG 2008 Discretionary Settlement (of which David Gare (the Company chairman) and his wife are the trustees) transferred 10,000 Ordinary Shares to David’s son Adrian Gare and a further 10,000 to his daughter, Debbie Walker, for nil consideration. Following the transaction, the DG 2008 Discretionary Settlement now has a total interest in 1,398,427 Ordinary Shares, representing approximately 8.81% of the Company's issued share capital.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

Download Notification (PDF)

For further information, please contact:

Instem plc
Phil Reason, CEO +44 (0) 1785 825600
Nigel Goldsmith, CFO  
N+1 Singer (Nominated Adviser & Broker) +44 (0) 20 7496 3000
Richard Lindley  
Nick Owen  
James White  
Wallbrook Financial PR Tel: +44 (0) 20 7933 8000
Paul Cornelius or
Sam Allen  
Helen Cresswell  
Paul Whittington  

About Instem

Instem is a leading supplier of IT applications and services to the early development healthcare market delivering compelling solutions for data collection, analysis and regulatory submissions management. Instem solutions are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem supports over 500 clients through offices in the United States, United Kingdom, France, Japan, China and India. 

To learn more about Instem solutions and its mission, please visit